News
Kogenate & Helixate Benefits Still Outweigh Risks
December 7, 2013; Posted by: webleed staff
The European Medicines Agency (EMA) has issued a press release highlighting the findings of their Pharmacoviglance Risk Assessment Committee (PRAC) on the factor VIII replacement medicines Kogenate and Helixate (both marketed by Bayer Pharmaceuticals AG).
The PRAC study concluded that current evidence did not show an increased risk of patients developing factor VIII inhibitors when compared to other available products for Hemophilia A. They found that the benefits from taking Kogenate and Helixate, both second-generation products, continue to outweigh risks.
To read the full press release from the EMA, click here.
3 Comments
My brother recommended I might like this website. He was totally right. This post truly made my day. You can’t imagine simply how much time I had spent for this info! Thanks!
Im not that much of a online reader to be honest but your blogs really nice, keep it up! I’ll go ahead and bookmark your site to come back later. Cheers.
Definitely loved you’re web site. Many thanks for sharing your blog.